Roche acquires Inflazome to gain control over inflammatory treatments

By Nikita Chaurasia  Date: 2020-09-22

Roche acquires Inflazome to gain control over inflammatory treatments

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million).

As per the agreement, Roche will acquire complete rights to Inflazome’s portfolio of oral NLRP3 inflammasome inhibitors, which are currently being developed for treating conditions such as Parkinson’s and other diseases, sources claimed.

Since its inception in 2016, Inflazome has been gaining worldwide recognition owing to its expertise in inflammasome inhibitors.  The firm is currently developing an oral NLRP3 inflammasome inhibitor in order to meet the unmet demands for various inflammatory diseases. In fact, the company claims the inhibitor has already completed Phase 1 human trails as well as various early-stage programmes.

Inflazome is also developing drugs which targets inflammasomes associated with arthritis, asthma, Alzheimer’s, Parkinson’s, and bowel disease as well as other chronic inflammatory conditions, cited sources with relevant information.

Matt Cooper, CEO at Inflazome was reported saying that the company is thrilled to enter a joint venture agreement with one of the prominent pharmaceutical giant Roche. He added that the acquisition will allow Inflazome to quickly and effectively develop its products in order to aid patients with debilitating diseases.

It is to be noted that earlier in July, Roche and its subsidiary Genentech Inc. entered a joint venture agreement with UCB, a Belgian company to produce and commercialize an antibody drug UCB0107 for treating Alzheimer’s disease

Several other pharmaceutical companies are also working on similar drug developments. In fact, IFM Therapeutics sold its subsidiaries with NLRP3 assets to Novartis International AG and Bristol Myers Squibb (BMS).

Source credits –

https://www.fiercebiotech.com/biotech/roche-pays-eu380m-for-nlrp3-biotech-inflazome-claiming-a-leading-position-hot-field

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW Group to opt for green steel in vehicle production from 2025

BMW Group to opt for green steel in vehicle production from 2025

By Nikita Chaurasia

As climatic changes and other environmental issues take center stage, the BMW Group, to minimize carbon dioxide (CO2) emissions at the core of its supply chain, has reportedly agreed to use green steel from Swedish firm H2 Green Steel beginning in 20...

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...